PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Trabanelli, Sara ^a,b   Lecciso, Mariangela ^a   Salvestrini, Valentina ^a   Cavo, Michele ^a   Očadlíková, Darina ^a   Lemoli, Roberto M ^c   Curti, Antonio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLTRYPTOPHAN L ISOFORM; GAMMA INTERFERON; IMMUNOGLOBULIN; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; KYNURENINE; N METHYLTRYPTOPHAN; PROSTAGLANDIN E2; UNCLASSIFIED DRUG; INDOLEAMINE 2,3-DIOXYGENASE 1, HUMAN; T LYMPHOCYTE RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO ACID SYNTHESIS; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CD3+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LYSATE; CELL MATURATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOPHENOTYPING; IMMUNOSTIMULATION; IN VITRO STUDY; MONOCYTE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TUMOR IMMUNITY; UPREGULATION; ACUTE MYELOBLASTIC LEUKEMIA; BIOSYNTHESIS; CELL CULTURE; CYTOTOXICITY; DRUG EFFECTS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LEUKEMIA; LYMPHOCYTE ACTIVATION; METABOLISM; T LYMPHOCYTE SUBPOPULATION;

CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; DINOPROSTONE; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOPHENOTYPING; IN VITRO TECHNIQUES; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; LEUKEMIA; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE ACTIVATION; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 84924560204     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/253191     Document Type: Article

References (92)

1. A. L. Mellor and D. H. Munn, "Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?" Immunology Today, vol. 20, no. 10, pp. 469-473, 1999.
2. S. Lob, A. Konigsrainer, R. Schafer, H.-G. Rammensee, G. Opelz, and P. Terness, "Levo-but not dextro-1-methyl tryp-tophan abrogates the IDO activity of human dendritic cells," Blood, vol. 111, no. 4, pp. 2152-2154, 2008.
3. G. Frumento, R. Rotondo, M. Tonetti, G. Damonte, U. Benatti, and G. B. Ferrara, "Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase," The Journal of Experimental Medicine, vol. 196, no. 4, pp. 459-468, 2002.
4. F. Fallarino, U. Grohmann, C. Vacca et al., "T cell apoptosis by kynurenines," Advances in Experimental Medicine and Biology, vol. 527, pp. 183-190, 2003.
5. F. Fallarino, U. Grohmann, S. You et al., "Tryptophan catabolism generates autoimmune-preventive regulatory T cells," Transplant Immunology, vol. 17, no. 1, pp. 58-60, 2006.
6. + T regulatory cells," Blood, vol. 109, no. 7, pp. 2871-2877, 2007.
7. D. H. Munn, M. Zhou, J. T. Attwood et al., "Prevention of allogeneic fetal rejection by tryptophan catabolism," Science, vol. 281, no. 5380, pp. 1191-1193, 1998.
8. E. Kwidzinski, J. Bunse, O. Aktas et al., "Indolamine 2, 3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation," The FASEB Journal, vol. 19, no. 10, pp. 1347-1349, 2005.
9. L. Catani, D. Sollazzo, S. Trabanelli et al., "Decreased expression of indoleamine 2, 3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia," Annals of Hematology, vol. 92, no. 1, pp. 67-78, 2013.
10. G. Brandacher, R. Margreiter, and D. Fuchs, "Implications of IFN-γ-mediated tryptophan catabolism on solid organ transplantation," Current Drug Metabolism, vol. 8, no. 3, pp. 273-282, 2007.
11. C. Uyttenhove, L. Pilotte, I. Theáte et al., "Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase," Nature Medicine, vol. 9, no. 10, pp. 1269-1274, 2003.
12. D. H. Munn and A. L. Mellor, "Indoleamine 2, 3-dioxygenase and tumor-induced tolerance," The Journal of Clinical Investigation, vol. 117, no. 5, pp. 1147-1154, 2007.
13. J. B. Katz, A. J. Muller, and G. C. Prendergast, "Indoleamine 2, 3-dioxygenase in T-cell tolerance and tumoral immune escape," Immunological Reviews, vol. 222, no. 1, pp. 206-221, 2008.
14. A. Curti, M. Aluigi, S. Pandolfi et al., "Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2, 3-dioxygenase," Leukemia, vol. 21, no. 2, pp. 353-355, 2007.
15. A. Curti, S. Trabanelli, V. Salvestrini, M. Baccarani, and R. M. Lemoli, "The role of indoleamine 2, 3-dioxygenase in the induction of immune tolerance: focus on hematology," Blood, vol. 113, no. 11, pp. 2394-2401, 2009.
16. J. Banchereau and A. K. Palucka, "Dendritic cells as therapeutic vaccines against cancer," Nature Reviews Immunology, vol. 5, no. 4, pp. 296-306, 2005.
17. F. Sallusto and A. Lanzavecchia, "Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α," The Journal of Experimental Medicine, vol. 179, no. 4, pp. 1109-1118, 1994.
18. G. Schuler, B. Schuler-Thurner, and R. M. Steinman, "The use of dendritic cells in cancer immunotherapy," Current Opinion in Immunology, vol. 15, no. 2, pp. 138-147, 2003.
19. 2-induced metalloproteinase-9 is essential for dendritic cell migration," Blood, vol. 111, no. 1, pp. 260-270, 2008.
20. D. Braun, R. S. Longman, and M. L. Albert, "A two-step induction of indoleamine 2, 3-dioxygenase (IDO) activity during dendritic-cell maturation," Blood, vol. 106, no. 7, pp. 2375-2381, 2005.
21. 2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell stimulatory capacity despite IDO," Journal of Leukocyte Biology, vol. 82, no. 5, pp. 1106-1114, 2007.
22. M. Wobser, H. Voigt, R. Houben et al., "Dendritic cell based antitumor vaccination: impact of functional indoleamine 2, 3-dioxygenase expression," Cancer Immunology, Immunotherapy, vol. 56, no. 7, pp. 1017-1024, 2007.
23. + monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination," British Journal of Haematology, vol. 121, no. 2, pp. 240-250, 2003.
24. D. J. Chung, M. Rossi, E. Romano et al., "Indoleamine 2, 3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells," Blood, vol. 114, no. 3, pp. 555-563, 2009.
25. + T cells via purinergic P2 receptor activation," Journal of Immunology, vol. 189, no. 3, pp. 1303-1310, 2012.
26. A. Curti, S. Trabanelli, C. Onofri et al., "Indoleamine 2, 3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells," Haematologica, vol. 95, no. 12, pp. 2022-2030, 2010.
27. H. Hedi and G. Norbert, "Inhibition of IL-6, TNF-α, and cyclooxygenase-2 protein expression by prostaglandin E2-induced IL-10 in bone marrow-derived dendritic cells," Cellular Immunology, vol. 228, no. 2, pp. 99-109, 2004.
28. H. Jonuleit, U. Kühn, G. Müller et al., "Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions," European Journal of Immunology, vol. 27, no. 12, pp. 3135-3142, 1997.
29. C. Rieser, G. Böck, H. Klocker, G. Bartsch, and M. Thurnher, "Prostaglandin E2 and tumor necrosis factor α cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production," The Journal of Experimental Medicine, vol. 186, no. 9, pp. 1603-1608, 1997.
30. A. F. Sheibanie, I. Tadmori, H. Jing, E. Vassiliou, and D. Ganea, "Prostaglandin E2 induces IL-23 production in bone marrow-derived dendritic cells," FASE B Journal, vol. 18, no. 11, pp. 1318-1320, 2004.
31. C. G. Figdor, I. J. M. De Vries, W. J. Lesterhuis, and C. J. M. Melief, "Dendritic cell immunotherapy: mapping the way," Nature Medicine, vol. 10, no. 5, pp. 475-480, 2004.
32. D. Ridgway, "The first 1000 dendritic cell vaccines," Cancer Investigation, vol. 21, no. 6, pp. 873-886, 2003.
33. P. Kaliński, C. M. U. Hilkens, E. A. Wierenga, and M. L. Kapsenberg, "T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal," Immunology Today, vol. 20, no. 12, pp. 561-567, 1999.
34. + T-c ell responses," Current Opinion in Immunology, vol. 16, no. 3, pp. 259-263, 2004.
35. D. A. Hokey, A. T. Larregina, G. Erdos, S. C. Watkins, and L. D. Falo Jr., "Tumor cell loaded type-1 polarized dendritic cells induce th1-mediated tumor immunity," Cancer Research, vol. 65, no. 21, pp. 10059-10067, 2005.
36. P. Hwu, M. X. Du, R. Lapointe, M. Do, M. W. Taylor, and H. A. Young, "Indoleamine 2, 3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation," Journal of Immunology, vol. 164, no. 7, pp. 3596-3599, 2000.
37. 2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy," Vaccine, vol. 20, no. 4, pp. A8-A22, 2002.
38. S. Trabanelli, D. Ocadlíková, M. Ciciarello et al., "The SOCS3-independent expression of IDO2 supports the homeostatic generation of t regulatory cells by human dendritic cells," Journal of Immunology, vol. 192, no. 3, pp. 1231-1240, 2014.
39. D. von Bubnoff, M. Scheler, H. Wilms, R. Fimmers, and T. Bieber, "Identification of IDO-positive and IDO-negative human dendritic cells after activation by various proinflammatory stimuli," The Journal of Immunology, vol. 186, no. 12, pp. 6701-6709, 2011.
40. E. Scandella, Y. Men, S. Gillessen, R. Förster, and M. Groettrup, "Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells," Blood, vol. 100, no. 4, pp. 1354-1361, 2002.
41. Y. Li, J. Xu, H. Zou, and C. Wang, "1-MT enhances potency of tumor cell lysate-pulsed dendritic cells against pancreatic adenocarcinoma by downregulating the percentage of Tregs," Journal of Huazhong University of Science and Technology: Medical Science, vol. 30, no. 3, pp. 344-348, 2010.
42. X. Ou, S. Cai, P. Liu et al., "Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2, 3-dioxygenase inhibitor, 1-MT," Journal of Cancer Research and Clinical Oncology, vol. 134, no. 5, pp. 525-533, 2008.
43. T. M. Westers, I. Houtenbos, A. A. van de Loosdrecht, and G. J. Ossenkoppele, "Principles of dendritic cell-based immunotherapy in myeloid leukemia," Immunobiology, vol. 211, no. 6-8, pp. 663-676, 2006.
44. S. Delluc, P. Hachem, S. Rusakiewicz et al., "Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response," Cancer Immunology, Immunotherapy, vol. 58, no. 10, pp. 1669-1677, 2009.
45. X. Zheng, J. Koropatnick, D. Chen et al., "Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model," International Journal of Cancer, vol. 132, no. 4, pp. 967-977, 2012.
46. M. Sioud, S. Sæbøe-Larssen, T. E. Hetland, J. Kærn, A. Mobergslien, and G. Kvalheim, "Silencing of indoleamine 2, 3-dioxygenaseenhances dendritic cell immunogenicity and anti-tumour immunity in cancer patients," International Journal of Oncology, vol. 43, no. 1, pp. 280-288, 2013.
47. A. L. Mellor and D. H. Munn, "Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?" Immunology Today, vol. 20, no. 10, pp. 469-473, 1999.
48. S. Lob, A. Konigsrainer, R. Schafer, H.-G. Rammensee, G. Opelz, and P. Terness, "Levo-but not dextro-1-methyl tryp-tophan abrogates the IDO activity of human dendritic cells," Blood, vol. 111, no. 4, pp. 2152-2154, 2008.
49. G. Frumento, R. Rotondo, M. Tonetti, G. Damonte, U. Benatti, and G. B. Ferrara, "Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase," The Journal of Experimental Medicine, vol. 196, no. 4, pp. 459-468, 2002.
50. F. Fallarino, U. Grohmann, C. Vacca et al., "T cell apoptosis by kynurenines," Advances in Experimental Medicine and Biology, vol. 527, pp. 183-190, 2003.
51. F. Fallarino, U. Grohmann, S. You et al., "Tryptophan catabolism generates autoimmune-preventive regulatory T cells," Transplant Immunology, vol. 17, no. 1, pp. 58-60, 2006.
52. + T regulatory cells," Blood, vol. 109, no. 7, pp. 2871-2877, 2007.
53. D. H. Munn, M. Zhou, J. T. Attwood et al., "Prevention of allogeneic fetal rejection by tryptophan catabolism," Science, vol. 281, no. 5380, pp. 1191-1193, 1998.
54. E. Kwidzinski, J. Bunse, O. Aktas et al., "Indolamine 2, 3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation," The FASEB Journal, vol. 19, no. 10, pp. 1347-1349, 2005.
55. L. Catani, D. Sollazzo, S. Trabanelli et al., "Decreased expression of indoleamine 2, 3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia," Annals of Hematology, vol. 92, no. 1, pp. 67-78, 2013.
56. G. Brandacher, R. Margreiter, and D. Fuchs, "Implications of IFN-γ-mediated tryptophan catabolism on solid organ transplantation," Current Drug Metabolism, vol. 8, no. 3, pp. 273-282, 2007.
57. C. Uyttenhove, L. Pilotte, I. Theáte et al., "Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase," Nature Medicine, vol. 9, no. 10, pp. 1269-1274, 2003.
58. D. H. Munn and A. L. Mellor, "Indoleamine 2, 3-dioxygenase and tumor-induced tolerance," The Journal of Clinical Investigation, vol. 117, no. 5, pp. 1147-1154, 2007.
59. J. B. Katz, A. J. Muller, and G. C. Prendergast, "Indoleamine 2, 3-dioxygenase in T-cell tolerance and tumoral immune escape," Immunological Reviews, vol. 222, no. 1, pp. 206-221, 2008.
60. A. Curti, M. Aluigi, S. Pandolfi et al., "Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2, 3-dioxygenase," Leukemia, vol. 21, no. 2, pp. 353-355, 2007.
61. A. Curti, S. Trabanelli, V. Salvestrini, M. Baccarani, and R. M. Lemoli, "The role of indoleamine 2, 3-dioxygenase in the induction of immune tolerance: focus on hematology," Blood, vol. 113, no. 11, pp. 2394-2401, 2009.
62. J. Banchereau and A. K. Palucka, "Dendritic cells as therapeutic vaccines against cancer," Nature Reviews Immunology, vol. 5, no. 4, pp. 296-306, 2005.
63. F. Sallusto and A. Lanzavecchia, "Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α," The Journal of Experimental Medicine, vol. 179, no. 4, pp. 1109-1118, 1994.
64. G. Schuler, B. Schuler-Thurner, and R. M. Steinman, "The use of dendritic cells in cancer immunotherapy," Current Opinion in Immunology, vol. 15, no. 2, pp. 138-147, 2003.
65. 2-induced metalloproteinase-9 is essential for dendritic cell migration," Blood, vol. 111, no. 1, pp. 260-270, 2008.
66. D. Braun, R. S. Longman, and M. L. Albert, "A two-step induction of indoleamine 2, 3-dioxygenase (IDO) activity during dendritic-cell maturation," Blood, vol. 106, no. 7, pp. 2375-2381, 2005.
67. 2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell stimulatory capacity despite IDO," Journal of Leukocyte Biology, vol. 82, no. 5, pp. 1106-1114, 2007.
68. M. Wobser, H. Voigt, R. Houben et al., "Dendritic cell based antitumor vaccination: impact of functional indoleamine 2, 3-dioxygenase expression," Cancer Immunology, Immunotherapy, vol. 56, no. 7, pp. 1017-1024, 2007.
69. + monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination," British Journal of Haematology, vol. 121, no. 2, pp. 240-250, 2003.
70. D. J. Chung, M. Rossi, E. Romano et al., "Indoleamine 2, 3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells," Blood, vol. 114, no. 3, pp. 555-563, 2009.
71. + T cells via purinergic P2 receptor activation," Journal of Immunology, vol. 189, no. 3, pp. 1303-1310, 2012.
72. A. Curti, S. Trabanelli, C. Onofri et al., "Indoleamine 2, 3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells," Haematologica, vol. 95, no. 12, pp. 2022-2030, 2010.
73. H. Hedi and G. Norbert, "Inhibition of IL-6, TNF-α, and cyclooxygenase-2 protein expression by prostaglandin E2-induced IL-10 in bone marrow-derived dendritic cells," Cellular Immunology, vol. 228, no. 2, pp. 99-109, 2004.
74. H. Jonuleit, U. Kühn, G. Müller et al., "Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions," European Journal of Immunology, vol. 27, no. 12, pp. 3135-3142, 1997.
75. C. Rieser, G. Böck, H. Klocker, G. Bartsch, and M. Thurnher, "Prostaglandin E2 and tumor necrosis factor α cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production," The Journal of Experimental Medicine, vol. 186, no. 9, pp. 1603-1608, 1997.
76. A. F. Sheibanie, I. Tadmori, H. Jing, E. Vassiliou, and D. Ganea, "Prostaglandin E2 induces IL-23 production in bone marrow-derived dendritic cells," FASE B Journal, vol. 18, no. 11, pp. 1318-1320, 2004.
77. C. G. Figdor, I. J. M. De Vries, W. J. Lesterhuis, and C. J. M. Melief, "Dendritic cell immunotherapy: mapping the way," Nature Medicine, vol. 10, no. 5, pp. 475-480, 2004.
78. D. Ridgway, "The first 1000 dendritic cell vaccines," Cancer Investigation, vol. 21, no. 6, pp. 873-886, 2003.
79. P. Kaliński, C. M. U. Hilkens, E. A. Wierenga, and M. L. Kapsenberg, "T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal," Immunology Today, vol. 20, no. 12, pp. 561-567, 1999.
80. + T-c ell responses," Current Opinion in Immunology, vol. 16, no. 3, pp. 259-263, 2004.
81. D. A. Hokey, A. T. Larregina, G. Erdos, S. C. Watkins, and L. D. Falo Jr., "Tumor cell loaded type-1 polarized dendritic cells induce th1-mediated tumor immunity," Cancer Research, vol. 65, no. 21, pp. 10059-10067, 2005.
82. P. Hwu, M. X. Du, R. Lapointe, M. Do, M. W. Taylor, and H. A. Young, "Indoleamine 2, 3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation," Journal of Immunology, vol. 164, no. 7, pp. 3596-3599, 2000.
83. 2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy," Vaccine, vol. 20, no. 4, pp. A8-A22, 2002.
84. S. Trabanelli, D. Ocadlíková, M. Ciciarello et al., "The SOCS3-independent expression of IDO2 supports the homeostatic generation of t regulatory cells by human dendritic cells," Journal of Immunology, vol. 192, no. 3, pp. 1231-1240, 2014.
85. D. von Bubnoff, M. Scheler, H. Wilms, R. Fimmers, and T. Bieber, "Identification of IDO-positive and IDO-negative human dendritic cells after activation by various proinflammatory stimuli," The Journal of Immunology, vol. 186, no. 12, pp. 6701-6709, 2011.
86. E. Scandella, Y. Men, S. Gillessen, R. Förster, and M. Groettrup, "Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells," Blood, vol. 100, no. 4, pp. 1354-1361, 2002.
87. Y. Li, J. Xu, H. Zou, and C. Wang, "1-MT enhances potency of tumor cell lysate-pulsed dendritic cells against pancreatic adenocarcinoma by downregulating the percentage of Tregs," Journal of Huazhong University of Science and Technology: Medical Science, vol. 30, no. 3, pp. 344-348, 2010.
88. X. Ou, S. Cai, P. Liu et al., "Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2, 3-dioxygenase inhibitor, 1-MT," Journal of Cancer Research and Clinical Oncology, vol. 134, no. 5, pp. 525-533, 2008.
89. T. M. Westers, I. Houtenbos, A. A. van de Loosdrecht, and G. J. Ossenkoppele, "Principles of dendritic cell-based immunotherapy in myeloid leukemia," Immunobiology, vol. 211, no. 6-8, pp. 663-676, 2006.
90. S. Delluc, P. Hachem, S. Rusakiewicz et al., "Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response," Cancer Immunology, Immunotherapy, vol. 58, no. 10, pp. 1669-1677, 2009.
91. X. Zheng, J. Koropatnick, D. Chen et al., "Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model," International Journal of Cancer, vol. 132, no. 4, pp. 967-977, 2012.
92. M. Sioud, S. Sæbøe-Larssen, T. E. Hetland, J. Kærn, A. Mobergslien, and G. Kvalheim, "Silencing of indoleamine 2, 3-dioxygenaseenhances dendritic cell immunogenicity and anti-tumour immunity in cancer patients," International Journal of Oncology, vol. 43, no. 1, pp. 280-288, 2013.